JP2024514308A5 - - Google Patents
Info
- Publication number
- JP2024514308A5 JP2024514308A5 JP2023560349A JP2023560349A JP2024514308A5 JP 2024514308 A5 JP2024514308 A5 JP 2024514308A5 JP 2023560349 A JP2023560349 A JP 2023560349A JP 2023560349 A JP2023560349 A JP 2023560349A JP 2024514308 A5 JP2024514308 A5 JP 2024514308A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- acid molecule
- domain
- molecule according
- variant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163168210P | 2021-03-30 | 2021-03-30 | |
| US63/168,210 | 2021-03-30 | ||
| PCT/US2022/022575 WO2022212525A2 (en) | 2021-03-30 | 2022-03-30 | Car t cell therapy and ifn gamma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024514308A JP2024514308A (ja) | 2024-04-01 |
| JP2024514308A5 true JP2024514308A5 (cg-RX-API-DMAC7.html) | 2025-04-08 |
Family
ID=81384825
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023560349A Pending JP2024514308A (ja) | 2021-03-30 | 2022-03-30 | CAR T細胞療法及びIFNγ |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240366662A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4314040A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024514308A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117242090A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022212525A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025235801A1 (en) | 2024-05-08 | 2025-11-13 | City Of Hope | Antibodies targeted to osteopontin and uses thereof for reducing resistance of solid tumors immune cell therapy |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2735456C (en) * | 2008-08-26 | 2021-11-16 | City Of Hope | Method and compositions for enhanced anti-tumor effector functioning of t cells |
| CN107074957B (zh) * | 2014-01-13 | 2021-05-07 | 希望之城公司 | 在Fc间隔物区中具有突变的嵌合抗原受体(CAR)及其使用方法 |
| ES2738705T3 (es) | 2014-09-19 | 2020-01-24 | Hope City | Linfocitos T de receptor de antígeno quimérico coestimulante que se dirigen a IL13R 2 |
| CN107429253B (zh) * | 2014-12-05 | 2021-11-05 | 希望之城公司 | Cs1靶向性嵌合抗原受体修饰的t细胞 |
| EP3747462A1 (en) | 2015-10-06 | 2020-12-09 | City of Hope | Chimeric antigen receptors targeted to psca |
| JP7085990B2 (ja) * | 2015-10-13 | 2022-06-17 | シティ・オブ・ホープ | クロロトキシンドメインを含むキメラ抗原レセプター |
| ES2909973T3 (es) | 2015-11-04 | 2022-05-10 | Hope City | Receptores quiméricos para el antígeno que se dirigen a HER2 |
| JP7189019B2 (ja) * | 2016-02-05 | 2022-12-13 | シティ・オブ・ホープ | 中枢神経系の癌の治療のための操作されたt細胞の投与 |
| WO2019148006A1 (en) * | 2018-01-26 | 2019-08-01 | City Of Hope | Chimeric antigen receptors and methods for reducing off target toxicity |
| US12410226B2 (en) | 2018-07-30 | 2025-09-09 | The Board Of Trustees Of The Leland Stanford Junior University | Interferon-gamma biased agonists |
| EP3830133A1 (en) * | 2018-08-01 | 2021-06-09 | City of Hope | Tag72 targeted chimeric antigen receptor modified t cells for treatment of tag72-positive tumors |
| US10918667B2 (en) * | 2018-11-20 | 2021-02-16 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expressing therapeutic agent and uses thereof |
| WO2021179967A1 (zh) * | 2020-03-09 | 2021-09-16 | 四川大学华西医院 | IFN-γ在制备抗肿瘤辅助药物中的应用 |
| EP4118106A1 (en) * | 2020-03-12 | 2023-01-18 | City of Hope | TARGETED CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS FOR TREATMENT OF IL13Ralpha2 POSITIVE MALIGNANCIES |
-
2022
- 2022-03-30 JP JP2023560349A patent/JP2024514308A/ja active Pending
- 2022-03-30 WO PCT/US2022/022575 patent/WO2022212525A2/en not_active Ceased
- 2022-03-30 CN CN202280026632.8A patent/CN117242090A/zh active Pending
- 2022-03-30 EP EP22718411.6A patent/EP4314040A2/en active Pending
- 2022-03-30 US US18/284,413 patent/US20240366662A1/en active Pending